| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
4-Chloro-3,5-dimethylphenoxyacetic acid is a phenoxyacetic acid derivative that acts as an auxin analog upon release from its masked precursor. The compound functions as a plant growth regulator through auxin signaling pathways. Auxins are plant hormones that regulate various aspects of plant growth and development, including cell elongation, division, and differentiation. The chloro and methyl substituents on the phenoxy ring contribute to its biological activity and receptor binding affinity.
|
|---|---|
| ln Vitro |
In vitro activity of 4-chloro-3,5-dimethylphenoxyacetic acid is primarily evaluated in plant-based systems. The parent masked auxin analog (compound 602) has been shown to effectively stimulate hypocotyl growth in wild-type seedlings. The hydrolysis product is the active form that mediates this auxin-like activity. The compound's activity as a plant growth regulator is assessed through standard auxin bioassays, including root elongation assays and hypocotyl growth assays in Arabidopsis thaliana or other model plant species.
|
| ln Vivo |
In vivo activity of 4-chloro-3,5-dimethylphenoxyacetic acid is evaluated in whole-plant systems. The parent compound 602 has demonstrated efficacy in stimulating hypocotyl growth in wild-type seedlings, indicating that the hydrolysis product is biologically active in planta. As an auxin analog, the compound would be expected to influence various auxin-mediated processes in plants, including root development, gravitropism, and apical dominance, depending on the application method and concentration.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 4-chloro-3,5-dimethylphenoxyacetic acid would typically employ plant-based receptor binding studies using auxin receptors such as TIR1 (Transport Inhibitor Response 1) or AFB (Auxin Signaling F-Box) proteins. Competitive binding assays with radiolabeled auxins (e.g., [³H]-IAA) are used to determine binding affinity. The compound's hydrolysis from the masked auxin analog can be monitored using HPLC or LC-MS to confirm the release of the active phenoxyacetic acid derivative.
|
| Cell Assay |
Cellular assays for 4-chloro-3,5-dimethylphenoxyacetic acid would be performed using plant cell cultures or seedling-based systems. Arabidopsis thaliana seedlings are grown on agar plates containing varying concentrations of the compound or its masked precursor. Hypocotyl elongation is measured after 5-7 days of growth under controlled light conditions. Root elongation assays are performed by measuring primary root length. Auxin-responsive reporter lines (e.g., DR5::GUS or DR5::GFP) can be used to visualize and quantify auxin signaling activation.
|
| Animal Protocol |
In vivo animal studies are not applicable for 4-chloro-3,5-dimethylphenoxyacetic acid as it is a plant growth regulator/auxin analog intended for plant research applications. The compound is not designed for animal or human therapeutic use. Studies are conducted in plant models, including Arabidopsis thaliana and other crop species, to evaluate auxin-like activity and effects on plant growth and development.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 4-chloro-3,5-dimethylphenoxyacetic acid are not relevant for its application as a plant growth regulator. In plant systems, the compound is released from its masked precursor through hydrolysis of the amide bond. The phenoxyacetic acid derivative is then available for interaction with auxin receptors in plant tissues. Standard plant uptake and translocation studies could be performed using radiolabeled compound to assess absorption, distribution, metabolism, and elimination in plant tissues.
|
| Toxicity/Toxicokinetics |
Toxicity data for 4-chloro-3,5-dimethylphenoxyacetic acid are limited in the published literature. As a phenoxyacetic acid derivative and auxin analog, the compound is primarily studied for plant science applications. Standard toxicological characterization in mammalian systems is not typically performed for compounds intended exclusively for plant research. The compound should be handled with standard laboratory safety precautions. It is not approved for human or veterinary use.
|
| References |
[1]. Savaldi-Goldstein S, Baiga TJ, Pojer F, Dabi T, Butterfield C, Parry G, Santner A, Dharmasiri N, Tao Y, Estelle M, Noel JP, Chory J. New auxin analogs with growth-promoting effects in intact plants reveal a chemical strategy to improve hormone delivery. Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15190-5.
|
| Additional Infomation |
4-Chloro-3,5-dimethylphenoxyacetic acid is the active hydrolysis product of masked auxin analog 602. The parent compound 602 effectively stimulates hypocotyl growth in wild-type seedlings, demonstrating auxin-like activity. This compound is of interest in plant science research for studying auxin signaling, plant growth regulation, and the development of auxin analogs with controlled release properties. The compound is not approved for clinical use; all applications remain in the plant research domain.
|
| Molecular Formula |
C10H11CLO3
|
|---|---|
| Molecular Weight |
214.65
|
| Exact Mass |
214.04
|
| CAS # |
19545-95-0
|
| PubChem CID |
89572
|
| Appearance |
White to off-white solid powder
|
| Density |
1.269g/cm3
|
| Boiling Point |
345.1ºC at 760mmHg
|
| Flash Point |
162.5ºC
|
| Vapour Pressure |
1.34E-05mmHg at 25°C
|
| Index of Refraction |
1.547
|
| LogP |
2.42
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
14
|
| Complexity |
196
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(C(=CC(=C1)OCC(=O)O)C)Cl
|
| InChi Key |
IJOSXVVFEKXIGN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H11ClO3/c1-6-3-8(14-5-9(12)13)4-7(2)10(6)11/h3-4H,5H2,1-2H3,(H,12,13)
|
| Chemical Name |
2-(4-chloro-3,5-dimethylphenoxy)acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6587 mL | 23.2937 mL | 46.5875 mL | |
| 5 mM | 0.9317 mL | 4.6587 mL | 9.3175 mL | |
| 10 mM | 0.4659 mL | 2.3294 mL | 4.6587 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
